Compare KVHI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | TARA |
|---|---|---|
| Founded | 1978 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 214.7M |
| IPO Year | 1996 | 2014 |
| Metric | KVHI | TARA |
|---|---|---|
| Price | $9.09 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 341.2K | ★ 795.0K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 38.25 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $9,622,000.00 | $2,948,000.00 |
| Revenue This Year | $28.90 | N/A |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | $294.83 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $2.97 |
| 52 Week High | $13.00 | $7.82 |
| Indicator | KVHI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 44.93 |
| Support Level | $8.80 | $3.62 |
| Resistance Level | $9.71 | $4.23 |
| Average True Range (ATR) | 0.72 | 0.23 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 55.84 | 64.96 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.